JR Rahn

Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers
Fintech Focus For June 11, 2021
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
Fintech Focus For June 11, 2021
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
Psyched: MindMed and Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Gets Back To Trading
First Psychedelics ETF Debuts On NEO Exchange

JR Rahn Recent News

How MindMed Uses Tech To Innovate, Deploy Psychedelic Mental Health Therapies
In an exclusive to Benzinga, Mind Medicine (MindMed) Inc (OTC: MMEDF), a leading medicine biotech company in psychedelics, on Tuesday revealed the introduction of a division known as Albert, to help research and develop an integrated platform for delivering psychedelic medicines, experiential therapies,
MindMed Submits Application To Cross-List At NASDAQ
Psychedelic drug development company MindMed (NEO: MMED) (OTCQB: MMEDF) has submitted an application to cross-list on NASDAQ.
Compass IPO: A 'Clear Bellwether For Growing Psychedelic Medicine Industry'
On Friday, UK-based mental health care company Compass Pathways (NASDAQ: CMPS) announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange.
MindMed To Begin Clinical Trials On Ayahuasca's Active Ingredient DMT
Biopharmaceutical and psychedelics research company Mind Medicine Inc. (NEO:MMED) (OTC: MMEDF)  announced Thursday that it will begin studying DMT’s effects on humans in a Phase 1 clinical trial conducted in collaboration with
'Psyched': New Leaf Brands Changes Name To Mydecine, Numinus Debuts On TSXV, MindMed To Research MDMA-LSD Interactions
Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry.
MindMed To Include MDMA to Research Portfolio
Neuro-pharmaceutical and psychedelics research company Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced Wednesday the inclusion of the psychoactive compound MDMA to its R&D pipeline.
What You Need To Know About MindMed's Bad LSD Trip 'Off-Switch'
Psychedelic pharmaceutical company Mind Medicine (MindMed) Inc. (OTC: MMEDF) (NEO:MMED) says it found an off-switch to end a bad trip.
MindMed Fastracks Phase 2 Trial Of LSD, Fending Off Mental Health Affliction, Impact Of COVID-19 Coronavirus
The COVID-19 coronavirus has prompted mass business closures, leading some economic forecasters to
MindMed Inks Deal With Switzerland University For Rights On LSD Research
MindMed Lists On NEO Exchange, Becomes First Psychedelics Company To Go Public
Bruce Linton Talks Psychedelics Investments, Microdosing And LSD: 'The Therapeutic Potential Of Psychedelics Is Greater Than Cannabinoids'